LEMAITRE VASCULAR INC
No SEC Form 4 filings for $LMAT in the last 30 days.
Conestoga Capital Advisors’ Q2 2026 investor letter discussed LeMaitre Vascular (NASDAQ:LMAT), citing 10% organic revenue growth, 72.1% gross margins, and adjusted EPS of $0.68 versus $0.66 consensus. Despite strong fundamentals, LMAT shares fell after earnings as investors took profits. LMAT closed Aug. 5 at $79, with a $1.81B market cap.
A market movers roundup highlights five stocks. LeMaitre (LMAT) fell 18.6% after Q2 results missed expectations and forecast was weak. ePlus (PLUS) dropped 5.1% despite Q2 2026 beating estimates. Booking (BKNG) rose 6.6% on Q2 results above estimates. Paymentus (PAY) fell 9.2% on cautious Q2 narrative. Vishay Intertechnology (VSH) slid 8.8% after mixed Q2 results, with revenue missing.
LeMaitre Vascular (NASDAQ: LMAT) shares fell 18.6% after Q2 results missed expectations and guidance weakened. Revenue was $70.38M vs $71.61M consensus, EPS was $0.74 vs $0.81. Q3 revenue guidance was $67.3M, about 3% below estimates, and full-year revenue was cut to $276.3M from $280M.
Over the past 7 days, alphai's AI scored 6 news stories mentioning LMAT (LEMAITRE VASCULAR INC). Coverage has skewed bearish: 1 bullish, 2 neutral, and 3 bearish.
Recent LMAT coverage spans financial news, earnings and market movers.
The article frames a post-earnings selloff despite beat results, implying near-term positioning risk even with solid fundamentals.
Near-term guidance miss is likely to keep downside pressure on estimates and sentiment until investors see stabilization.
The earnings and guidance miss is the primary driver of today’s sharp downside, increasing near-term estimate and sentiment risk.
The miss plus softer next-quarter guidance is a near-term demand and execution negative, likely keeping downside pressure until follow-through appears in subsequent quarters.
The 8-K combines an earnings/guidance print with dividend and buyback details, setting a clear near-term earnings expectation path.
alphai scores every news story that mentions LMAT with an AI model for sentiment and relevance, and aggregates insider trades from LEMAITRE VASCULAR INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Conestoga Capital Advisors’ Q2 2026 investor letter discussed LeMaitre Vascular (NASDAQ:LMAT), citing 10% organic revenue growth, 72.1% gross margins, and adjusted EPS of $0.68 versus $0.66 consensus. Despite strong fundamentals, LMAT shares fell after earnings as investors took profits. LMAT closed Aug. 5 at $79, with a $1.81B market cap.
4 min readA market movers roundup highlights five stocks. LeMaitre (LMAT) fell 18.6% after Q2 results missed expectations and forecast was weak. ePlus (PLUS) dropped 5.1% despite Q2 2026 beating estimates. Booking (BKNG) rose 6.6% on Q2 results above estimates. Paymentus (PAY) fell 9.2% on cautious Q2 narrative. Vishay Intertechnology (VSH) slid 8.8% after mixed Q2 results, with revenue missing.
2 min readLeMaitre Vascular (NASDAQ: LMAT) shares fell 18.6% after Q2 results missed expectations and guidance weakened. Revenue was $70.38M vs $71.61M consensus, EPS was $0.74 vs $0.81. Q3 revenue guidance was $67.3M, about 3% below estimates, and full-year revenue was cut to $276.3M from $280M.
4 min readLeMaitre Vascular (NASDAQ:LMAT) reported Q2 CY2026 revenue of $70.38 million, up 9.6% year on year but below Wall Street estimates. Next-quarter revenue guidance was $67.3 million, about 3% under analysts’ expectations. GAAP EPS was $0.74, 8.3% below consensus. The stock fell 11.6% to $93.53 after results.
4 min readLEMAITRE VASCULAR INC (LMAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d320964dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LeMaitre Q2 2026 Financial Results BURLINGTON, MA, August 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly divid
6 min readLeMaitre Vascular (NASDAQ: LMAT) will report earnings Tuesday after market close. The prior quarter revenue was $66.55 million, up 11.2% year over year, and it met revenue expectations. For the upcoming quarter, analysts expect revenue growth of 11.5% y/y. The average analyst price target is $118.75 versus $101.32.
4 min readThrivent Financial for Lutherans significantly increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 492.0% in the fourth quarter, now owning 88,950 shares valued at $7.21 million. The article also details other institutional investor activity, LeMaitre Vascular's financial performance, recent insider selling, and current analyst ratings, with the stock holding a "Moderate Buy" consensus.
3 min readLeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in June. Management will attend the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026. The company specializes in devices for peripheral vascular disease.
2 min readLeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that its management will participate in two investor conferences in June 2026. The company will attend the Jefferies Global Healthcare Conference in New York on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference in Miami Beach on June 10, 2026, delivering scheduled presentations at both events. LeMaitre, a provider of devices for peripheral vascular disease, aims to engage with investors and share company updates.
2 min readGSA Capital Partners LLP significantly increased its stake in LeMaitre Vascular, Inc., now holding 21,234 shares valued at $1.72 million. This comes as other institutional investors have also adjusted their positions, and company insiders have recently sold shares. Analysts have a "Moderate Buy" consensus rating for LeMaitre Vascular, with a price target of $112.60.
3 min read
